These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33430227)

  • 21. Transitional and temporal changes in the mucosal and submucosal intestinal microbiota in advanced Crohn's disease of the terminal ileum.
    Chiodini RJ; Dowd SE; Barron JN; Galandiuk S; Davis B; Glassing A
    J Med Microbiol; 2018 Apr; 67(4):549-559. PubMed ID: 29458679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut microbiota in the pathogenesis of inflammatory bowel disease.
    Nishida A; Inoue R; Inatomi O; Bamba S; Naito Y; Andoh A
    Clin J Gastroenterol; 2018 Feb; 11(1):1-10. PubMed ID: 29285689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The epidemiology and the pathogenesis of inflammatory bowel disease.
    Karlinger K; Györke T; Makö E; Mester A; Tarján Z
    Eur J Radiol; 2000 Sep; 35(3):154-67. PubMed ID: 11000558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's?
    Haag LM; Siegmund B
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):399-409. PubMed ID: 24913380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on intestinal microbiota in Crohn's disease 2017: Mechanisms, clinical application, adverse reactions, and outlook.
    Shen Z; Zhu C; Quan Y; Yuan W; Wu S; Yang Z; Luo W; Tan B; Wang X
    J Gastroenterol Hepatol; 2017 Nov; 32(11):1804-1812. PubMed ID: 28677158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial barrier dysfunction and microbial dysbiosis: exploring the pathogenesis and therapeutic strategies for Crohn's disease.
    Akkoç T
    Tissue Barriers; 2024 Aug; ():2390705. PubMed ID: 39185541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models.
    Balmus IM; Ciobica A; Trifan A; Stanciu C
    Saudi J Gastroenterol; 2016; 22(1):3-17. PubMed ID: 26831601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention.
    Aleksandrova K; Romero-Mosquera B; Hernandez V
    Nutrients; 2017 Aug; 9(9):. PubMed ID: 28867793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs-Current Evidences and Further Aspects to Unravel.
    Moret-Tatay I; Iborra M; Cerrillo E; Tortosa L; Nos P; Beltrán B
    Oxid Med Cell Longev; 2016; 2016():2325162. PubMed ID: 26823944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Insights into the Pathogenesis of Inflammatory Bowel Diseases: Genetics and Microbiota].
    Marchukov D; Misselwitz B
    Ther Umsch; 2019 Jan; 75(5):273-279. PubMed ID: 30700240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal Microbiota Transplantation for Inflammatory Bowel Disease.
    Lopez J; Grinspan A
    Gastroenterol Hepatol (N Y); 2016 Jun; 12(6):374-9. PubMed ID: 27493597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut dysbiosis and paediatric Crohn's disease.
    Brusaferro A; Cavalli E; Farinelli E; Cozzali R; Principi N; Esposito S
    J Infect; 2019 Jan; 78(1):1-7. PubMed ID: 30336176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metagenomic Characterization of Microbial Communities
    Pedamallu CS; Bhatt AS; Bullman S; Fowler S; Freeman SS; Durand J; Jung J; Duke F; Manzo V; Cai D; Ananthakrishnan A; Ojesina AI; Ramachandran A; Gevers D; Xavier RJ; Bhan AK; Meyerson M; Yajnik V
    Cell Mol Gastroenterol Hepatol; 2016 Sep; 2(5):563-566.e5. PubMed ID: 28174737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Environmental influences on the onset and clinical course of Crohn's disease-part 1: an overview of external risk factors.
    Dam AN; Berg AM; Farraye FA
    Gastroenterol Hepatol (N Y); 2013 Nov; 9(11):711-7. PubMed ID: 24764788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are We Ready to Reclassify Crohn's Disease Using Molecular Classification?
    Kamal S; Parkash N; Beattie W; Christensen B; Segal JP
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies.
    Khanna S; Raffals LE
    Gastroenterol Clin North Am; 2017 Sep; 46(3):481-492. PubMed ID: 28838410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease.
    Hedin CR; van der Gast CJ; Stagg AJ; Lindsay JO; Whelan K
    Gut Microbes; 2017 Jul; 8(4):359-365. PubMed ID: 28112583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evidence for fungus in Crohn's disease pathogenesis.
    Miyoshi J; Sofia MA; Pierre JF
    Clin J Gastroenterol; 2018 Dec; 11(6):449-456. PubMed ID: 30027368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in epidemiological features between ulcerative colitis and Crohn's disease: The early life-programmed versus late dysbiosis hypothesis.
    Beaugerie L; Langholz E; Nyboe-Andersen N; Pigneur B; Sokol H;
    Med Hypotheses; 2018 Jun; 115():19-21. PubMed ID: 29685190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.
    DeFilippis EM; Longman R; Harbus M; Dannenberg K; Scherl EJ
    Curr Gastroenterol Rep; 2016 Mar; 18(3):13. PubMed ID: 26908281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.